Published in Heart Fail Rev on January 01, 2005
Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev (2010) 1.05
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension (2009) 0.99
Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension (2014) 0.95
Role of vasopressin in rat distal colon function. J Physiol (2006) 0.86
Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol (2007) 0.84
Breakthrough in heart failure with preserved ejection fraction: are we there yet? Korean J Intern Med (2015) 0.78
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design. Clin Cardiol (2015) 0.75
Conserved Ankyrin Repeat Proteins and Their NIMA Kinase Partners Regulate Extracellular Matrix Remodeling and Intracellular Trafficking in Caenorhabditis elegans. Genetics (2016) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation (2000) 3.22
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res (2002) 2.98
Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol (1989) 2.95
Structural correlate of atrial fibrillation in human patients. Cardiovasc Res (2002) 2.55
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med (1992) 2.54
Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation (1999) 2.03
Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation (1998) 1.96
Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation (1997) 1.93
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest (1997) 1.83
Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation (2004) 1.71
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 1.63
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 1.50
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology (2002) 1.45
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol (1995) 1.34
The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol (1996) 1.32
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res (1997) 1.24
Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation (2004) 1.24
Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension (2001) 1.24
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol (2004) 1.21
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol (1993) 1.17
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res (1992) 1.12
Aldosterone production is activated in failing ventricle in humans. Circulation (2001) 1.08
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res (2002) 1.06
Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest (1991) 1.06
Monitoring tissue repair and fibrosis from a distance. Circulation (1997) 1.06
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension (2001) 1.03
Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol (1995) 1.01
Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem (1996) 0.98
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol (2001) 0.98
The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol (1995) 0.96
Role of myocytes in myocardial collagen production. Hypertension (2001) 0.95
Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation (2000) 0.94
Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension (2000) 0.89
Aldosterone and the heart: towards a physiological function? Cardiovasc Res (1999) 0.88
Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens (1994) 0.87
Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation (2000) 0.86
Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs (2002) 0.85
Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol (1997) 0.85
Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol (1999) 0.83
Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol (2004) 0.83
Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J Mol Cell Cardiol (1993) 0.82
Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Investig (1993) 0.81
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol (1993) 0.80
Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta (1996) 0.80
Cardiac procedures in acute care situations. Med Clin North Am (1981) 0.75
Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace (2007) 1.05
Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail (2005) 0.98
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol (2007) 0.84
Impact of French 'Comités de Protection des Personnes' on the readability of informed consent documents (ICD) in biomedical research: more information, but not better information. Fundam Clin Pharmacol (2005) 0.84
Development of a French epidemiological surveillance system of workers producing or handling engineered nanomaterials in the workplace. J Occup Environ Med (2011) 0.83
The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol (2010) 0.77
French adaptation and preliminary validation of a questionnaire to evaluate understanding of informed consent documents in phase I biomedical research. Fundam Clin Pharmacol (2006) 0.77
Trough-to-peak ratio, smoothness index and morning-to-evening ratio: why, which and when? J Hypertens (2003) 0.75
[Proposal of a tool for providing patients with the main results of clinical research studies]. Therapie (2006) 0.75
Reproductive disorders in hairdressers and cosmetologists: a meta-analytical approach. J Occup Health (2015) 0.75
[Performance evaluation of a tool for institutional protocol quality assurance]. Therapie (2006) 0.75